KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments: 2015-2025

Historic Change in Acquisitions & Divestments for Arbutus Biopharma (ABUS) over the last 8 years, with Sep 2025 value amounting to $41.3 million.

  • Arbutus Biopharma's Change in Acquisitions & Divestments rose 45.61% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.1 million, marking a year-over-year increase of 22.01%. This contributed to the annual value of $164.6 million for FY2024, which is 24.47% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Change in Acquisitions & Divestments stood at $41.3 million, which was down 6.39% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Change in Acquisitions & Divestments registered a high of $56.7 million during Q4 2024, and its lowest value of $2.0 million during Q1 2022.
  • Its 3-year average for Change in Acquisitions & Divestments is $38.9 million, with a median of $41.3 million in 2025.
  • As far as peak fluctuations go, Arbutus Biopharma's Change in Acquisitions & Divestments slumped by 90.17% in 2022, and later soared by 1,750.00% in 2023.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Change in Acquisitions & Divestments stood at $20.0 million in 2021, then surged by 30.00% to $26.0 million in 2022, then soared by 77.86% to $46.2 million in 2023, then climbed by 22.58% to $56.7 million in 2024, then surged by 45.61% to $41.3 million in 2025.
  • Its Change in Acquisitions & Divestments was $41.3 million in Q3 2025, compared to $44.1 million in Q2 2025 and $46.1 million in Q1 2025.